FDA Determines Regulatory Review Period for ORTHO-EVRA Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of ORTHO-EVRA, a human drug product, following a submission to the Director of Patents and Trademarks at the US Department of Commerce.